Cargando…
Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
[Image: see text] The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase associated with various kinds of leukemia and solid tumors. Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents. Usin...
Autores principales: | Zeng, Li-Fan, Zhang, Ruo-Yu, Yu, Zhi-Hong, Li, Sijiu, Wu, Li, Gunawan, Andrea M., Lane, Brandon S., Mali, Raghuveer S., Li, Xingjun, Chan, Rebecca J., Kapur, Reuben, Wells, Clark D., Zhang, Zhong-Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136714/ https://www.ncbi.nlm.nih.gov/pubmed/25003231 http://dx.doi.org/10.1021/jm5006176 |
Ejemplares similares
-
Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012) -
Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice
por: Sharma, Namit, et al.
Publicado: (2014) -
SHP2 phosphatase as a novel therapeutic target for melanoma treatment
por: Zhang, Ruo-Yu, et al.
Publicado: (2016) -
Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated
SHP2 Mutations
por: Yu, Zhi-Hong, et al.
Publicado: (2014) -
The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)